Transvaginal Mesh: Chronic Pelvic Pain

Background and Product Issues

Surgical mesh for pelvic repair was first cleared by the FDA in the 1990s–2000s via the 510(k) process, which allowed approval based on substantial equivalence to earlier devices (some of which were later withdrawn). Manufacturers marketed the products as safe, minimally invasive alternatives to traditional “native tissue” repair surgery. Products included slings for SUI and larger meshes for POP, sold under brand names such as:

• Ethicon (Johnson & Johnson): Prolift, Gynemesh, TVT
• C.R. Bard: Avaulta
• Boston Scientific: Pinnacle, Uphold, Obtryx
• American Medical Systems (Endo): Perigee, Apogee, Elevate
• Others: Coloplast, Cook Medical, Mentor (ObTape)

The mesh was designed to integrate with tissue but often shrank, hardened, or migrated, causing chronic issues. Complications frequently required multiple revision surgeries, sometimes with incomplete removal of the mesh.

Common Complications and Injuries

Women reported a wide range of serious side effects, many emerging months or years after implantation:

• Mesh erosion or extrusion into the vagina, bladder, bowel, or other organs
• Chronic pelvic, vaginal, or nerve pain
• Organ perforation (bladder, bowel, urethra)
• Recurrent infections and abscesses
• Pain during intercourse (dyspareunia)
• Urinary problems (incontinence, retention, urgency)
• Bleeding, scarring, and fistula formation
• Emotional distress, loss of quality of life, and need for ongoing medical care

The FDA received over 1,000 adverse event reports by 2008, rising dramatically thereafter. Many women underwent repeated surgeries, with some experiencing permanent damage despite interventions.

Regulatory Actions

The FDA issued escalating warnings:

• 2008: Public Health Notification highlighting complications.
• July 2011: Updated Safety Communication stating that “serious complications associated with transvaginal placement of surgical mesh for POP are not rare” and questioning whether benefits outweighed risks compared to non-mesh repairs.
• 2016–2019: Required post-market surveillance studies; ultimately ordered manufacturers to stop selling transvaginal mesh for POP repair in April 2019 due to insufficient evidence of safety and effectiveness. Mesh for SUI (mid-urethral slings) faced stricter scrutiny but was not fully banned.

These actions fueled litigation by highlighting manufacturers’ alleged failure to adequately test products or warn physicians and patients.

The Litigation: Scale and Structure

Lawsuits alleged defective design, inadequate warnings, negligent marketing, and failure to conduct proper clinical trials. Claims were brought under product liability, negligence, and breach of warranty theories.

• Over 100,000–107,000 individual lawsuits were filed nationwide between roughly 2010 and 2022.
• The Judicial Panel on Multidistrict Litigation (JPML) consolidated cases into seven (or eight) federal MDLs, primarily in the U.S. District Court for the Southern District of West Virginia under Judge Joseph R. Goodwin. Key MDLs included those against Ethicon (MDL 2327), C.R. Bard (MDL 2187), Boston Scientific (MDL 2326), American Medical Systems (MDL 2325), and others.
• Bellwether trials tested representative cases, producing some large plaintiff verdicts (often reduced or settled on appeal).
• The federal MDLs largely concluded by 2021–2022, with most cases resolved through global or individual settlements. Unresolved cases were remanded to state courts.

State court litigation continued in parallel, with coordinated proceedings in some jurisdictions.